NCT04039230
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who have received prior irinotecan; Patients with progressive central nervous system (CNS) metastatic disease – see trial for details
https://ClinicalTrials.gov/show/NCT04039230